$1.91
0.79% today
NYSE, Feb 05, 04:23 pm CET
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

ACELYRIN Stock price

$1.89
-1.60 45.85% 1M
-3.22 63.01% 6M
-1.25 39.81% YTD
-6.25 76.78% 1Y
-16.11 89.50% 3Y
-16.11 89.50% 5Y
-16.11 89.50% 10Y
NYSE, Closing price Tue, Feb 04 2025
-0.03 1.56%
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

Key metrics

Market capitalization $189.62m
Enterprise Value $-366.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.42
P/B ratio (TTM) P/B ratio 0.36
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-324.85m
Free Cash Flow (TTM) Free Cash Flow $-257.23m
Cash position $562.37m
EPS (TTM) EPS $-2.68
P/E forward negative
Short interest 7.42%
Show more

Is ACELYRIN a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

ACELYRIN Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ACELYRIN forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a ACELYRIN forecast:

Buy
57%
Hold
43%

Financial data from ACELYRIN

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.33 0.33
-
-
-0.33 -0.33
-
-
- Selling and Administrative Expenses 75 75
-
-
- Research and Development Expense 249 249
-
-
-325 -325
-
-
- Depreciation and Amortization 0.33 0.33
-
-
EBIT (Operating Income) EBIT -325 -325
-
-
Net Profit -264 -264
-
-

In millions USD.

Don't miss a Thing! We will send you all news about ACELYRIN directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACELYRIN Stock News

Neutral
GlobeNewsWire
30 days ago
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
Neutral
GlobeNewsWire
about one month ago
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its pote...
Neutral
GlobeNewsWire
about 2 months ago
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance
More ACELYRIN News

Company Profile

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Head office United States
CEO Mina Kim
Employees 130
Founded 2020
Website www.acelyrin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today